KR850000525A - 재조합 dna기법에 의한 인체 igf 및 egf제조 - Google Patents

재조합 dna기법에 의한 인체 igf 및 egf제조 Download PDF

Info

Publication number
KR850000525A
KR850000525A KR1019840003134A KR840003134A KR850000525A KR 850000525 A KR850000525 A KR 850000525A KR 1019840003134 A KR1019840003134 A KR 1019840003134A KR 840003134 A KR840003134 A KR 840003134A KR 850000525 A KR850000525 A KR 850000525A
Authority
KR
South Korea
Prior art keywords
human igf
human
host cell
recombinant
egf
Prior art date
Application number
KR1019840003134A
Other languages
English (en)
Inventor
몬리 제임스 (외 1)
Original Assignee
월터 에이취. 드레거
제넨테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27053789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850000525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 월터 에이취. 드레거, 제넨테크 인코포레이티드 filed Critical 월터 에이취. 드레거
Publication of KR850000525A publication Critical patent/KR850000525A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음.

Description

재조합 DNA기법에 의한 인체 IGF 및 EGF제조
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 인체 인슐린 유사 성장인자(IGF)용 표현 벡터조합시 사용된 화학합성 DNA임.
제2도는 제1도의 DNA의 완전한 이중 구조임.
제3도는 EcoRI와 PstI 및 BamHI로 제한시킨 후의 제2도의 DNA 단편임.
제4도는 제3도의 1과 2 부분을 pBR322에 연접시키는 도식임.

Claims (10)

  1. 재조합 숙주로부터 표현, 조작 그리고 분비의 생성물인 성숙한 인체 IGF.
  2. 효모 알파인자 DNA에서 유도된 N-종지서열 전구체를 처리하고, 성숙한 인체 IGF를 재조합 효모 숙주로 분비시키는 상기 서열전구체로 가지는 재조합 효모숙주 표현물로서 성숙한 인체 IGF.
  3. 재조합 숙주로 생성된 인체 IGF.
  4. 재조합 숙주로 생성된 인체 EGF.
  5. 적당한 숙주세포에서 인체 IGF 암호인 DNA서열 표현이 가능한 복제성 표현벡터를 제조하고, 상기 벡터로 숙주세포 배양체를 형질변이시켜서 재조합 숙주세포를 얻고, 상기 인체 IGF 암호화된 DNA서열의 표현이 가능한 조건하에서 상기 재조합 숙주세포 배양체를 배양시켜서 인체 IGF를 생성하고, 이 인체 IGF를 회수하는 단계로 되는 인체 IGF 제조방법.
  6. 적당한 숙주세포에서 인체 EGF암호인 DNA서열 표현이 가능한 복제성 표현벡터를 제조하고, 상기 벡터로 숙주세포배양체를 형질변이시켜서 재조합 숙주세포를 얻고, 상기 인체 EGF 암호화된 DNA서열의 표현이 가능한 조건하에서 상기 재조합 숙주세포배양체를 배양시켜서 인체 EGF를 생성하고, 이 인체 EGF를 회수하는 단계로 되는 인체 EGF 제조방법.
  7. 인체 IGF 암호화 DNA서열을 형질변이 재조합 숙주에서 표현시킬 수 있는 표현 벡터.
  8. 인체 EGF 암호화 DNA서열을 형질변이 재조합 숙주에서 표현시킬 수 있는 표현벡터.
  9. 청구범위 8 또는 9의 벡터로 형질변이시킨 재조합 숙주.
  10. 본질적으로 성숙한 인체 IGF로 되는 제약조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840003134A 1983-06-06 1984-06-05 재조합 dna기법에 의한 인체 igf 및 egf제조 KR850000525A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50135383A 1983-06-06 1983-06-06
US06/501353 1983-06-06
US50607883A 1983-06-20 1983-06-20
US06/506078 1983-06-20

Publications (1)

Publication Number Publication Date
KR850000525A true KR850000525A (ko) 1985-02-27

Family

ID=27053789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840003134A KR850000525A (ko) 1983-06-06 1984-06-05 재조합 dna기법에 의한 인체 igf 및 egf제조

Country Status (10)

Country Link
US (3) US6331414B1 (ko)
EP (1) EP0128733B1 (ko)
JP (2) JP2608870B2 (ko)
KR (1) KR850000525A (ko)
AU (1) AU594301B2 (ko)
DE (1) DE3485693D1 (ko)
DK (1) DK172480B1 (ko)
ES (1) ES8603955A1 (ko)
IE (1) IE58317B1 (ko)
IL (1) IL71991A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101687815B1 (ko) 2015-06-19 2016-12-20 이영근 파력 발전 장치 및 이 파력 발전 장치를 복수 개 연결한 파력 발전 시스템

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
EP0561137B1 (en) * 1983-04-25 2002-07-03 Chiron Corporation Hybrid DNA Synthesis of Mature Insulin-like Growth Factors
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
JPS60501989A (ja) * 1983-08-10 1985-11-21 アムジエン インシュリン様成長因子の微生物発現
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0154434B1 (en) * 1984-02-17 1993-01-27 Genentech, Inc. Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
JPS61502657A (ja) * 1984-07-13 1986-11-20 チロン　コ−ポレイシヨン プレプロインシュリン様成長因子１及び２
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
EP0193112A3 (en) * 1985-02-22 1987-02-25 The Trustees Of Columbia University In The City Of New York Cdna encoding mammalian insulin-like growth factor ii
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
US5242811A (en) * 1985-03-26 1993-09-07 Biogen, Inc. Production of human somatomedin C
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
EP0219814B1 (en) * 1985-10-21 1991-09-11 Fujisawa Pharmaceutical Co., Ltd. Process for production of isulin-like growth factor i and plasmid for production thereof
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
IN165717B (ko) * 1986-08-07 1989-12-23 Battelle Memorial Institute
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
DK175535B1 (da) * 1987-03-04 2004-11-29 Daiichi Suntory Pharma Co Ltd Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid
ATE112684T1 (de) * 1987-04-28 1994-10-15 Boehringer Mannheim Gmbh Verwendung von igf-ii zur behandlung von knochenkrankheiten.
US5688763A (en) * 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
US5226912A (en) 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US5472702A (en) * 1987-08-26 1995-12-05 United States Surgical Corporation Sterilization of growth factors
US5222978A (en) 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5102789A (en) * 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
KR920003787B1 (ko) * 1990-03-05 1992-05-14 한국과학기술 연구원 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992004363A1 (en) * 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2059245C (en) * 1991-02-08 2004-07-06 Michael P. Chesterfield Method and apparatus for calendering and coating/filling sutures
CA2105064A1 (en) * 1991-04-01 1992-10-02 Martin Anthony Gleeson Genes which influence pichia proteolytic activity, and uses therefor
AU2368892A (en) * 1991-07-29 1993-03-02 British Bio-Technology Limited Igf-ii analogues
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
ATE297214T1 (de) * 1993-09-20 2005-06-15 Celtrix Pharma Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
EP0779927A1 (en) * 1994-09-08 1997-06-25 Chiron Corporation A method of improved production of insulin-like growth factor
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US5789547A (en) * 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US7087580B2 (en) * 1998-04-23 2006-08-08 Genesense Technologies, Inc. Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
DE60042550D1 (de) 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
US20030100505A1 (en) * 1999-11-01 2003-05-29 Chiron Corporation Compositions and methods of therapy for IGF-I-responsive conditions
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
US20030035788A1 (en) 2000-09-19 2003-02-20 Desmond Mascarenhas Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
EP1435986B1 (en) 2001-09-18 2008-01-02 Bioexpertise, Llc Igf-binding protein-derived peptide
EP1667521B1 (en) 2003-09-12 2011-12-07 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
US7595160B2 (en) * 2004-01-13 2009-09-29 U.S. Genomics, Inc. Analyte detection using barcoded polymers
US7977048B2 (en) 2004-01-13 2011-07-12 Pathogenetix, Inc. Detection and quantification of analytes in solution using polymers
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
EP2132217A2 (en) 2007-02-26 2009-12-16 Alltech Associates Inc. Ultra-fast chromatography
EP2148695B1 (en) 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
EP1988154B1 (en) 2007-04-30 2013-08-21 Ajinomoto Co., Inc. Method for producing human insulin-like growth factor I
EP2164509A1 (en) * 2007-06-08 2010-03-24 Massachusetts Institute of Technology Igf for the treatment of rett syndrome and synaptic disorders
US20090192554A1 (en) 2008-01-29 2009-07-30 Confluent Surgical, Inc. Bioabsorbable block copolymer
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CN102471769A (zh) 2009-07-17 2012-05-23 亚伦·T.·塔波尔 用于具有美容功能的细胞的遗传修饰以提高美容外观的方法和组合物
CA2780554C (en) 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20190151411A1 (en) 2017-09-11 2019-05-23 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases
KR102015116B1 (ko) * 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
US20230381285A1 (en) 2020-10-19 2023-11-30 Oak Hill Bio Ltd Compositions suitable for use in neonates
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210872B2 (ko) 1973-07-14 1977-03-26
NL7607683A (nl) 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4652525A (en) 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4565785A (en) 1978-06-08 1986-01-21 The President And Fellows Of Harvard College Recombinant DNA molecule
FR2441659A1 (fr) 1978-11-14 1980-06-13 Anvar Nouveaux plasmides hybrides et microorganismes les contenant
IL60184A (en) 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4431740A (en) 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
GR70279B (ko) * 1979-09-12 1982-09-03 Univ California
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4350764A (en) 1980-03-10 1982-09-21 The Regents Of The University Of California Microbiological synthesis of beta endorphin
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE53166B1 (en) 1980-08-05 1988-08-03 Searle & Co Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
JPS57200343A (en) 1981-06-02 1982-12-08 Wakunaga Yakuhin Kk 27-desamidosecretin and its preparation
IE53517B1 (en) 1981-06-17 1988-12-07 Celltech Ltd Process for the production of a polypeptide
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
WO1983004030A1 (en) 1982-05-06 1983-11-24 Applied Molecular Genetics, Inc. The manufacture and expression of genes for urogastrone and polypeptide analogs thereof
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4530904A (en) 1982-09-03 1985-07-23 Eli Lilly And Company Method for conferring bacteriophage resistance to bacteria
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
GB8308483D0 (en) 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US5015575A (en) 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
EP0561137B1 (en) * 1983-04-25 2002-07-03 Chiron Corporation Hybrid DNA Synthesis of Mature Insulin-like Growth Factors
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
NL8302324A (nl) 1983-06-30 1985-01-16 Rijksuniversiteit Utrecht De Escherichia coli stam, een voor deze stam karakteristiek plasmide, een werkwijze ter bereiding van dit plasmide, een precursor van een somatomedine, alsmede een groeibevorderend preparaat.
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
DK108685A (da) 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
JPS61502657A (ja) 1984-07-13 1986-11-20 チロン　コ−ポレイシヨン プレプロインシュリン様成長因子１及び２
US5084384A (en) * 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101687815B1 (ko) 2015-06-19 2016-12-20 이영근 파력 발전 장치 및 이 파력 발전 장치를 복수 개 연결한 파력 발전 시스템

Also Published As

Publication number Publication date
EP0128733A1 (en) 1984-12-19
DE3485693D1 (de) 1992-06-11
JPH0759578A (ja) 1995-03-07
IE841400L (en) 1984-12-06
IL71991A0 (en) 1984-10-31
EP0128733B1 (en) 1992-05-06
DK276184A (da) 1985-01-21
US6331414B1 (en) 2001-12-18
ES8603955A1 (es) 1986-01-16
ES533170A0 (es) 1986-01-16
JP2608870B2 (ja) 1997-05-14
AU2913384A (en) 1984-12-13
JPS6069029A (ja) 1985-04-19
IL71991A (en) 1994-05-30
DK276184D0 (da) 1984-06-04
DK172480B1 (da) 1998-10-05
USRE39355E1 (en) 2006-10-17
US6331609B1 (en) 2001-12-18
IE58317B1 (en) 1993-09-08
AU594301B2 (en) 1990-03-08

Similar Documents

Publication Publication Date Title
KR850000525A (ko) 재조합 dna기법에 의한 인체 igf 및 egf제조
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
DE3583824D1 (de) Vorlaeufer des insulins, verfahren zu seiner herstellung und verfahren zur herstellung von humaninsulin aus solchen vorlaeufern des insulins.
DE3781765T2 (de) Verfahren zur herstellung eines polypeptides.
DK224587D0 (da) Ekstracellulaer superoxiddismutase (ec-sod), dna-fragment, der indkoder ec-sod, fremgangsmaade til fremstilling af ec-sod samt anvendelse af ec-sod
EP0048970A3 (en) Polypeptides, process for their microbial production, intermediates therefor and compositions containing them
ATE318917T1 (de) Verfahren zur bakteriellen herstellung von heterologen polypeptiden mit disulfidbrücke
IL80022A (en) Cloned human basic fibroblast growth factor, methods for its preparation, compositions containing it, dna sequences encoding therefor and vectors and host cells containing said dna
KR850004273A (ko) 안정성이 증대된 재조합 감마 인터페론 및 그의 제조방법
CA2022752A1 (en) Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
KR840008697A (ko) 상동 효모 신호를 이용한 이종단백질의 합성, 분비 및 표현매개체 제조방법
PT97383A (pt) Processo para a producao de uma cadeia de globina, de um seu fragmento de ligacao e de hemoglobina, e de composicoes de hemoglobina
ATE371027T1 (de) Expressions- und sekretionsvektor für menschliches interferon alpha und verfahren zur herstellung von interferon alpha durch anwendung desselben
ES8304430A1 (es) "un procedimiento para obtener insulina humana".
Hartmanis et al. Stability of solvent formation in Clostridium acetobutylicum during repeated subculturing
ATE145004T1 (de) Verfahren zur herstellung von luciferase durch rekombinante expression eines luciferase- kodierenden gens
EP0280407A3 (en) Process for the production of recombinant polypeptides with porcine growth hormone activity
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
KR870007280A (ko) 바실러스에서의 사람 혈청 알부민의 제조방법
DE3850456D1 (de) Klonierung des isoamylaseenzym kodierenden Gens und seine Verwendung zur Herstellung dieses Enzyms.
ATE202381T1 (de) Neue prosequenz zur sekretion heterologer proteine aus hefezellen
WO1994011518A3 (en) Methods for converting a, ab, and b blood types to o blood type
RU93057957A (ru) Бактерии, способ получения бактерий, вакцина
EP0183272A3 (en) Vector capable of efficient gene expression and utilization of such vector
DE69429858D1 (de) Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application